Blockchain Registration Transaction Record

Lexaria's Drug Delivery Tech Shows Promise in GLP-1 Study, Reduces Side Effects

Lexaria Bioscience reports new Phase 1b data showing its DehydraTECH drug delivery platform improves tolerability & body composition vs. Rybelsus® in GLP-1 study.

This news matters because it highlights a potential breakthrough in managing the side effects of blockbuster GLP-1 drugs like Ozempic and Wegovy. A major barrier to wider adoption and patient adherence for these highly effective weight-loss and diabetes medications is their common and often severe gastrointestinal side effects, such as nausea and vomiting. Lexaria's DehydraTECH platform demonstrated a clear reduction in these adverse events in its clinical study. If this technology can be successfully partnered with or adopted by major pharmaceutical companies, it could lead to next-generation GLP-1 therapies that are equally effective but far more tolerable for patients. This would improve treatment outcomes, increase patient compliance, and potentially expand access to these life-changing medications for millions more people struggling with obesity and type-2 diabetes. Furthermore, the incidental finding of blood pressure reduction with their CBD formulation points to versatile applications of their delivery platform beyond the massive GLP-1 market.